.jpg){kind=logo}
Pinpointing sources of unlinked SARS-CoV-2 cases supports rapid public health response. Using high-quality genetic fingerprinting, DeepMARK™ can enable rapid community case tracing by identifying transmission paths, clusters, and viral contagiousness. DeepMARK™’s increased sensitivity also allows for asymptomatic and recovering cases to be more thoroughly evaluated for contagiousness.
For researchers studying contagiousness, SARS-CoV-2 sgRNA is a recognized marker of active viral replication linked with contagiousness2 and offers several advantages. While viral culture is the gold standard, it is slow, expensive, and requires a biosafety level 3 (BSL3) laboratory, requirements prohibitive for the vast majority of samples. Using DeepMARK™, clinical samples can be safely and efficiently profiled using a simple workflow.
SgRNA as a marker of viral replication is also a well-recognized efficacy measurement in SARS-CoV-2 vaccine development3. Thus, comprehensive sgRNA profiling by DeepMARK™ could facilitate more efficient vaccine discovery.
“Genetic fingerprinting enables quicker and deeper analysis of viral spread. This tool has enhanced our capacity to understand SARS-CoV-2 precisely and contributes to the ongoing fight against COVID-19.” said A/Prof Hsu Li Yang, Vice Dean, Global Health, Saw Swee Hock School of Public Health, National University of Singapore.
DeepMARK™ is part of Lucence’s suite of SARS-CoV-2 molecular diagnostics. Lucence also makes the SAFER™ Sample Kit, a saliva stabilization kit with reported 36% higher sensitivity for detecting COVID-19 compared to nasopharyngeal swabbing4.
About DeepMARK™
DeepMARK™ is a next-generation sequencing (NGS) assay kit for the qualitative analysis of SARS-CoV-2 RNA. For Investigational Use Only. The performance characteristics of this product have not been established.
About Lucence
Lucence is a molecular diagnostics company that makes state-of-the-art, highly sensitive tests for disease detection and treatment selection. Headquartered in Singapore and California, Lucence’s services are delivered worldwide through an accredited central laboratory. For more information, contact enquiry@lucence.com or visit www.lucence.com/deepmark.
References
1. https://www.nature.com/articles/s41586-020-2196-x
2. https://wwwnc.cdc.gov/eid/article/26/11/20-3219_article
3. https://www.nejm.org/doi/full/10.1056/NEJMoa2024671
4. https://www.medrxiv.org/content/10.1101/2020.08.13.20173807v1
